(Q53538258)

15 May 2018

title

Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C. (English)

1 reference

15 May 2018

1 reference

5

1 reference

15 May 2018

David A. Hecht

9

1 reference

15 May 2018

Nezam Afdhal

object named as

Nezam H Afdhal

6

0 references

author name string

Paul J Pockros

1

1 reference

15 May 2018

Eugene R Schiff

2

1 reference

15 May 2018

Mitchell L Shiffman

3

1 reference

15 May 2018

John G McHutchison

4

1 reference

15 May 2018

Manana Makhviladze

7

1 reference

15 May 2018

Mira Huyghe

8

1 reference

15 May 2018

Tilman Oltersdorf

10

1 reference

15 May 2018

David A Shapiro

11

1 reference

15 May 2018

language of work or name

English

0 references

publication date

1 August 2007

1 reference

15 May 2018

published in

Hepatology

1 reference

15 May 2018

volume

46

1 reference

15 May 2018

issue

2

1 reference

15 May 2018

page(s)

324-329

1 reference

15 May 2018

Cell death: critical control points

cites work

1 reference

7 January 2021

Characterization of IDN-6556 (3-[2-(2-tert-butyl-phenylaminooxalyl)-amino]-propionylamino]-4-oxo-5-(2,3,5,6-tetrafluoro-phenoxy)-pentanoic acid): a liver-targeted caspase inhibitor

1 reference

7 January 2021

The Caspase Inhibitor IDN-6556 Attenuates Hepatic Injury and Fibrosis in the Bile Duct Ligated Mouse

1 reference

7 January 2021

The caspase inhibitor IDN-6556 prevents caspase activation and apoptosis in sinusoidal endothelial cells during liver preservation injury

1 reference

7 January 2021

Caspase activation correlates with the degree of inflammatory liver injury in chronic hepatitis C virus infection

1 reference

7 January 2021

Fas-mediated hepatocyte apoptosis is increased by hepatitis C virus infection and alcohol consumption, and may be associated with hepatic fibrosis: mechanisms of liver cell injury in chronic hepatitis C virus infection

1 reference

7 January 2021

CD95-induced apoptosis in human liver disease

1 reference

7 January 2021

Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis

1 reference

7 January 2021

Apoptosis in alcoholic hepatitis: a novel therapeutic target?

1 reference

7 January 2021

Hepatocyte apoptosis is a pathologic feature of human alcoholic hepatitis

1 reference

7 January 2021

Alcohol consumption induces hepatocyte apoptosis in patients with chronic hepatitis C infection

1 reference

7 January 2021

Clinical and biological relevance of hepatocyte apoptosis in alcoholic hepatitis

1 reference

7 January 2021

Apoptotic pathways in primary biliary cirrhosis and autoimmune hepatitis.

1 reference

7 January 2021

Apoptosis of sinusoidal endothelial cells occurs during liver preservation injury by a caspase-dependent mechanism

1 reference

7 January 2021

Fas receptor is upregulated in livers from non-heart-beating donors

1 reference

7 January 2021

First clinical trial of a novel caspase inhibitor: anti-apoptotic caspase inhibitor, IDN-6556, improves liver enzymes.

1 reference

7 January 2021

Anti-Fas induces hepatic chemokines and promotes inflammation by an NF-kappa B-independent, caspase-3-dependent pathway

1 reference

7 January 2021

Apoptosis: the nexus of liver injury and fibrosis.

1 reference

7 January 2021

Silymarin treatment of viral hepatitis: a systematic review

1 reference

7 January 2021

Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial.

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.21664

1 reference

15 May 2018

1 reference

15 May 2018